GlassScriptPhysician profile
Megan Day
NPI 1295184323
$675.16
in general payments reported to CMS, 2019-2025
17 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.95 · 2023: $261 · 2024: $74.89 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $176.03 | 2022-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $81.25 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $59.17 | 2022-2025 | Zepbound, Mounjaro |
| Medtronic, INC. | $53.77 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Novo Nordisk INC | $44.37 | 2024-2025 | Ozempic, Rybelsus |
| Sequel Med Tech, LLC | $34.44 | 2025 | Twiist |
| Esperion Therapeutics, INC. | $30.80 | 2023-2025 | Nexletol |
| Beta Bionics, INC. | $29.60 | 2024 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $22.42 | 2025 | Yorvipath |
| Corcept Therapeutics | $22.16 | 2025 | Korlym |
| Insulet Corporation | $19.37 | 2025 | Omnipod |
| Madrigal Pharmaceuticals | $18.65 | 2025 | Rezdiffra |
| Abbvie INC. | $18.27 | 2023 | Synthroid |
| Bayer Healthcare Pharmaceuticals INC. | $17.37 | 2023 | |
| Alexion Pharmaceuticals, INC. | $16.44 | 2023 | Strensiq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $16.00 | 2022 | |
| Horizon Therapeutics Plc | $15.05 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.